Darovasertib

Darovasertib is an investigational new drug that is being evaluated for the treatment of metastatic uveal melanoma and other cancers.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Darovasertib is an investigational new drug that is being evaluated for the treatment of metastatic uveal melanoma and other cancers. It is a first-in-class oral, small molecule inhibitor of protein kinase C (PKC). It selectively targets PKC activation by constitutively active mutant forms GNAQ or GNA11, which are present in approximately 90% of uveal melanoma cases.

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to darovasertib for the treatment of uveal melanoma on May 2, 2022, highlighting its potential to address an unmet medical need in this rare and aggressive form of eye cancer. As of 2024, darovasertib is in clinical development, with ongoing phase 1/2 trials evaluating its efficacy both as a monotherapy and in combination with other agents, such as binimetinib and crizotinib.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330141294 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001330141294 · captured 2025-12-29 · ledger · version history

Cite this page as: encyclopegia.org, “Darovasertib”, snapshot enwiki-001330141294. https://encyclopegia.org/a/darovasertib

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.